ALT Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $52,000.00
Insider Selling (Last 12 Months): $110,475.90

Altimmune Insider Trading History Chart

This chart shows the insider buying and selling history at Altimmune by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$52kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Altimmune Share Price & Price History

Current Price: $5.92
Price Change: Price Increase of +0.72 (13.85%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for ALT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$5.92Closing price on 03/15/25:

SEC Filings (Institutional Ownership Changes) for Altimmune (NASDAQ:ALT)

78.05% of Altimmune stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$22Mbought$7.25MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Altimmune logo
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More on Altimmune

Today's Range

Now: $5.92
Low: $5.36
High: $6.05

50 Day Range

MA: $6.48
Low: $5.20
High: $7.45

52 Week Range

Now: $5.92
Low: $5.14
High: $11.16

Volume

12,149,179 shs

Average Volume

3,000,387 shs

Market Capitalization

$455.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Who are the company insiders with the largest holdings of Altimmune?

Altimmune's top insider investors include:
  1. David Drutz (Director)
  2. Matthew Scott Harris (Insider)
  3. Gregory L Weaver (CFO)
Learn More about top insider investors at Altimmune.

Who are the major institutional investors of Altimmune?

Altimmune's top institutional investors include:
  1. Ameriprise Financial Inc. — 7.39%
  2. Vanguard Group Inc. — 6.23%
  3. Geode Capital Management LLC — 2.33%
  4. Bellevue Group AG — 1.33%
  5. Northern Trust Corp — 0.94%
  6. Dimensional Fund Advisors LP — 0.89%
Learn More about top institutional investors of Altimmune stock.

Which institutional investors are selling Altimmune stock?

Within the previous quarter, ALT stock was sold by these institutional investors:
  1. Vanguard Group Inc.
  2. D. E. Shaw & Co. Inc.
  3. Exchange Traded Concepts LLC
  4. Squarepoint Ops LLC
  5. Schroder Investment Management Group
  6. Los Angeles Capital Management LLC
  7. BNP Paribas Financial Markets
  8. Valence8 US LP

Which institutional investors are buying Altimmune stock?

Within the previous quarter, ALT stock was bought by institutional investors including:
  1. Ameriprise Financial Inc.
  2. Invesco Ltd.
  3. Millennium Management LLC
  4. Two Sigma Investments LP
  5. Citadel Advisors LLC
  6. Ensign Peak Advisors Inc
  7. PEAK6 LLC
  8. Focus Partners Wealth
In the previous year, these company insiders have bought Altimmune stock:
  1. David Drutz (Director)
  2. Matthew Scott Harris (Insider)
  3. Gregory L Weaver (CFO)
Learn More investors buying Altimmune stock.